PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cellsLinglong Yin, Xiong Li|Journal of Experimental & Clinical Cancer Research|2018Cited by 126
AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancerLinglong Yin, Xiong Li|Journal of Experimental & Clinical Cancer Research|2023Cited by 12